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A Non-randomized, Observational Trial of Short-term Pre-operative Endocrine Therapy in ER Positive 
Breast Cancer to Investigate Changes in Genomic Expression Using the Oncotype DX® Recurrence Score®
Bleznak A. D.,1,2 Dellers E. A.,1 Glenn-Porter B.,1 Kimmel S.,1 Chung H.,1 Yoshizawa C.,3 Burke E.,3 Davison D. S.,3 Chao C.3 (1Lehigh Valley Health Network, Allentown, Pa.; 2University of South Florida School of Medicine, Tampa, Fla.;  3Genomic Health, Inc., Redwood City, Calif )
L E H I G H  V A L L E Y  H E A L T H  N E T W O R K
Background
•  Pre-operative systemic treatment is commonly employed for women with locally 
 advanced breast cancer. Women with early-stage, hormone receptor-positive breast 
cancer whose resections may be delayed for 30 to 60 days while they undergo pre- 
operative evaluation, may benefi t from receiving pre-operative endocrine therapy while 
awaiting surgery. 
•  Short-term neoadjuvant endocrine therapy has been reported to be well tolerated and 
results in a modest clinical response. 1,2
•  One rationale for not initiating such treatment is that the cancer may be rendered less 
chemosensitive should fi nal pathology dictate that adjuvant chemotherapy would be 
benefi cial. 
•  The 21-gene Recurrence Score (RS) assay has been shown to be a predictor of both 
chemo- and endocrine-therapy responsiveness and may be useful as an indicator of 
sensitivity during and after neoadjuvant therapy.3-6
Objective
•  Compare core biopsy and excisional surgical specimens with respect to RS and single 
gene RT-PCR scores for ER, PR and HER2, in a cohort of women receiving short-term, 
pre-operative endocrine therapy
Materials and Methods
•  Treatment: 4-8 weeks of daily letrozole (2.5 mg ) for post-menopausal women or 
tamoxifen (20 mg) for pre-menopausal women
•  Clinical response was assessed by ultrasound (US) and clinical examination.
   Complete response (CR): no tumor on palpation and/or imaging
   Partial response (PR): ≥30% reduction
   Progressive disease (PD): >20% increase
   Stable disease (SD): other than above
•  The Oncotype DX breast cancer assay was performed on core biopsy and excisional 
specimens by standardized methods in the Genomic Health Clinical Laboratory. 
   All samples were reviewed by board certifi ed pathologists. When necessary, samples 
were manually micro-dissected to enrich for tumor. 
   The 21-gene RS assay, including ER, PR, and HER2 gene expression, was assessed 
by RT-PCR.
•  Single gene cut-point values (reference normalized expression, log2 scale):
   ER: Negative <6.5, Positive ≥6.5
   PR: Negative <5.5, Positive ≥5.5
   HER2: Negative <10.7, Equivocal 10.7 - <11.5, Positive ≥11.5
•  This is an exploratory, hypothesis-generating study. Scatter plots of core biopsy vs 
 excisional specimen results were produced. Pearson correlation coeffi cients and 95% 
confi dence intervals (CI) were calculated to assess correlation from core biopsies to 
 excisional specimens. Paired t-tests were performed on a post-hoc basis to examine if 
there were any directionally consistent changes.
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Results
•  21 patients consented to this study and initiated short-term neoadjuvant therapy:
   19 completed therapy, underwent surgery, and had evaluable core biopsy and excisional 
specimens
   2 patients were excluded from this analysis:
  •  1 patient had no residual cancer in the excisional specimen
  •  1 patient did not have evaluable core and excisional specimens
Strengths and Limitations
Strengths
•  Prospective study of changes in  
biomarkers in early-stage, ER+ breast 
cancer treated with endocrine therapy
Limitations
•  Small sample size (n=19)
•  Only 3 pre-menopausal patients; too few 
to examine potential differences by 
 menopausal status. 
•  Potential selection bias
•  Only 1/19 patients in high RS group.
•  Hypothesis tests not pre-specifi ed
Summary and Discussion
•  Expression levels of ER, PR, and HER2 from core biopsies and excisional specimens 
were correlated (Pearson correlation coeffi cients, r = 0.87, 0.72, and 0.77, respec-
tively), as was RS (r = 0.89), following short term neoadjuvant endocrine therapy.
•  In this study, on average, therapy reduced the expression of ER and PR, while HER2 
 expression was unchanged. The changes in ER and PR expression contributed to a 
modest increase (mean = 2.8 units, p = 0.003) in the Oncotype DX RS. 
•  The prognostic and predictive capability of the Oncotype DX RS in ER-positive, early-
stage breast cancer has been demonstrated in multiple clinical studies; none of these 
patients had received  neoadjuvant therapy.
   There are no data on the prognostic or predictive ability of the RS from tumor 
 samples obtained after neoadjuvant therapy.
   The clinical signifi cance of the changes in ER, PR and RS observed in this study is 
therefore unclear.
Conclusions
In this small, hypothesis-generating study:
•  Expression of ER and PR both decreased by small but statistically signifi cant amounts, 
which  contributed to a small but statistically signifi cant increase in RS (2.8 units).  
•  The clinical signifi cance of these observed changes are unclear.
•  Decreases in ER have been observed following short term aromatase inhibitor 
 treatment in some studies,7-8 but not others.9
Table 1: Study Eligibility Criteria
† Assessed by IHC * HER2 status 0 or 1+ by IHC or negative by FISH
Criterion Description Eligible Values
Age 35 – 85 Years
ECOG Performance Status (PS) 0 , 1, or 2
Tumor Size Greater than 0.5 cm in diameter, sonographically visible
HER2 Status* Negative
Table 2: Baseline Characteristics for 19 T1, N0, M0 Patients
† Assessed by IHC *Assessed by IHC/FISH
Variable n (%) Variable n (%)
Single Gene Status Menopausal Status
ER Positive† 19 (100%) Pre 3 (16%)
PR Positive† 19 (100%) Post 16 (84%)
HER2* Age (years)
0,1+ 17 (89%) <50 4 (21%)
2+/FISH- 2 (11%) 50-59 3 (16%)
Tumor Grade 60-69 7 (37%)
Well Differentiated 9 (47%) 70-79 5 (26%)
Moderately Differentiated 8 (42%) Endocrine Therapy
Poorly Differentiated 2 (11%) Tamoxifen 3 (16%)
Letrozole 16 (84%)
Figure 1: Clinical 
Response by 
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Figure 2: Correlation of 
 Pre-Neoadjuvant RS with 
 Post-Neoadjuvant RS
Mean change in RS = 2.8 unit (normalized expression, log2 scale) 
 increase (95% CI 1.1-4.6), p=0.003 from paired t-test
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Figure 3: Correlation of 
 Pre-Neoadjuvant ER with 
 Post-Neoadjuvant ER
Mean change in ER = 0.64 unit (normalized expression, log2 scale) 
decrease (95%CI 0.32-0.96), p<0.001 from paired t-test
Trend toward higher ER in PR vs SD/PD (mean difference= 0.8 units, 
p=0.064).































Figure 4: Correlation of 
 Pre-Neoadjuvant PR with 
 Post-Neoadjuvant PR
Mean change in PR = 1.25 unit (normalized expression, log2 scale) 
decrease (95% CI 0.64-1.86), p<0.001 from paired t-test































Figure 5: Correlation of 
 Pre-Neoadjuvant HER2 with 
 Post-Neoadjuvant HER2
No change in HER2 ([mean change = 0.09 unit (normalized expression, 
log2 scale]), 95% CI -0.16 to 0.35, p=0.45 from paired t-test
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